@article {351,
	title = {Drug Review: Abrocitinib},
	journal = {International Journal of Pharmacology and Clinical Sciences},
	volume = {12},
	year = {2023},
	month = {September 2023},
	pages = {14-16},
	type = {Research Article},
	chapter = {14},
	abstract = {<p class="rtejustify">Registrations: Abrocitinib had been registered in the following countries United States of America (USA), United Kingdom (U.K.), Canada, and Saudi Arabia (SA). Trade name (USA.); CIBINQO{\textregistered} Registration number (S.A.); Not Available. Insurance Drug Formulary (S.A.); Not covered (28.1.2023). General Information: Registered Company: By Pfizer company. Regulatory Status: R.X. Mechanism of Action: It is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). Indication Approved (Labeled) indication Atopic dermatitis (Moderate to Severe), Refractory to other systemic drug products, including biologics, or when the use of such therapies is inadvisable<sup>.[3]</sup>\&nbsp;<strong>Read more..</strong></p>
},
	doi = {10.5530/ijpcs.2023.12.3},
	author = {Juman Alsaab}
}
